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CONCLUSIONS: Migraine is a costly condition, both in
terms of direct and indirect costs. Better therapeutic control
should dramatically reduce costs related to healthcare re-
source consumption and lost workdays due to migraine.
TPM2
ONE-YEAR REHOSPITALISATION RATE
IN SCHIZOPHRENIA AND 
SCHIZOAFFECTIVE DISORDER
Tavcar R, Dernovsek M, Zvan V
University Psychiatric Hospital, Ljubljana-Polje, Slovenia
OBJECTIVES: Rehospitalisation rate is one indicator of
outcome. Schizophrenia has a high relapse and rehospi-
talisation rate (up to 50% per year). Antipsychotic main-
tenance treatment is essential for relapse prevention. The
aim of our naturalistic follow-up study was to find out
the predictors of one-year rehospitalisation in patients
with schizophrenia or schizoaffective disorder.
METHODS: All patients discharged in 1994 from the
University Psychiatric Hospital in Ljubljana, Slovenia,
were followed up for one year. Symptoms were assessed
with Present State Examination. Data on rehospitalisa-
tion were taken from the national Registry of Psychiatric
Inpatients. Predictors of rehospitalisation were assessed
with Cox proportional hazards survival analysis.
RESULTS: Included were 447 patients (202 males and 245
females) with a mean age of 39.1 years and 5.9 previous
hospitalisations. The majority of patients (n  322) were
discharged with depot antipsychotics, 82 were on classical
oral antipsychotics while 43 were prescribed atypical agents
clozapine or risperidone. In one year 122 patients (27.3%)
were rehospitalised, which is comparable to the results of
other studies. The following risk factors were found: diag-
nosis of schizoaffective disorder (Cox regression coefficient
(B)  0.56, p  0.027), frequent previous hospitalisations
(B  0.31, p  0.021), inappropriate behaviour (B  0.43,
p  0.004), and oral classical antipsychotics versus depot or
atypical agents (B  0.37, p  0.047).
CONCLUSIONS: This study yields some insight into the
influences on rehospitalisation rate. Although rehospital-
isation seems to depend mostly on disease-related factors,
the choice of antipsychotic drugs, which is a modifiable
risk factor, may be important too.
TPM3
THE EFFECT OF OBSERVATION DURATION ON 
CLAIMS-BASED RISK ADJUSTMENT SCORES
Andrews K, Powell-Threets K, Zhao Z
Center for Outcomes Measurement and Performance 
Assessment, Merck-Medco Managed Care, L.L.C., Montvale, 
NJ, USA
OBJECTIVES: To determine the association between
claims-based risk adjustment scores and duration of obser-
vation and to ascertain whether statistical control for any
association is possible.
METHODS: We analyzed 18 months of claims data (1/1/
1996–6/30/1998) from a large American company. We re-
stricted the study population to those individuals that were
continuously eligible for benefit coverage for the entire 18
months (n  42,054). Drug-based risk adjustment scores
(Chronic Disease Score) and medical-based risk adjustment
scores (Elixhauser Index) were calculated at 3,6,9,12, and
18 months.
RESULTS: We found a pronounced effect of time, with
the population’s mean Chronic Disease Score increasing
23% (p  0.05) in 1 year and the population’s mean Elix-
hauser Index increasing by 19% (p  0.05). More impor-
tantly, the relationship between time and the mean risk ad-
justment scores was linear and demonstrated a strong
correlation (r2  0.96).
CONCLUSIONS: The high correlation between some risk
adjustment scores and duration of observation precludes
direct comparisons between individuals with different
lengths of observation. However, statistical control, e.g.,
standardized scores derived from linear regression, for the
bias due to length of observation is possible. Thus, restrict-
ing analyses to individuals with a common duration of ob-
servation may be unnecessary.
TPM4
EVALUATION OF HIV/AIDS TREATMENT 
REGIMENS AND CONCOMITANT 
THERAPY USING A LARGE PHARMACY 
CLAIMS DATABASE
Hutchison S, Beno C
Information Operations, PCS Health Systems, Inc., Scottsdale, 
AZ, USA
OBJECTIVES: To examine initial and ending treatment
regimens for HIV/AIDS patients, and determine rates of
treatment for opportunistic infections.
METHODS: We conducted a retrospective database
study using a large pharmacy claims database. We identi-
fied patients newly treated for HIV/AIDS during the first
6 months of 1998 (N  494), then examined their phar-
maceutical prescription fill patterns for the calendar year
1998. All patients had continuous insurance eligibility
from July 1997 through December 1998, and did not fill
prescriptions for AIDS drugs between July 1997 and De-
cember 1997.
RESULTS: Most patients initiated therapy on a 2- or 3-
drug regimen (41% and 42% respectively). Most patients
continued on the same treatment regimen they initiated on
(67% to 71%) with exception of patients initiating on a 2-
nucleoside regimen (only 45% continued on this regimen
to the end of the study period). The most common aug-
mentation involved adding a protease inhibitor (14%) fol-
lowed by adding a nucleoside (11%). PCP, Candidiasis,
MAC, and depression were the most frequently treated
concomitant therapy conditions. The rate of treatment for
comorbid conditions varied considerably depending on the
patient’s initial treatment regimen.
CONCLUSIONS: This study provides direct evidence of
regimens used to treat HIV/AIDS, estimates of switching
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